Drug provides relief to those with overactive bladder

Article

The FDA recently approved trospium (Sanctura, Indevus Pharmaceuticals/Odyssey Pharmaceuticals) for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency. The product launch of trospium is expected to take place during the third quarter of 2004.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.